 SAN FRANCISCO, Feb. 24, 2021 GLOBE NEWSWIRE -- 89bio, Inc. Nasdaq: ETNB, a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Companys Management will provide a corporate update and participate in one-on-one investor meetings at the Raymond James 42nd Annual Institutional Investors Conference on Wednesday, March 3, 2021 at 12:30 PM ET. 